FATE THERAPEUTICS INC (FATE)
US31189P1021 - Common Stock
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 55.85M 77.70% | 96.3M 72.43% | 63.533M -34.03% | 13.677M -78.47% | 4.019M -70.61% | 3.4M -15.40% | 16.184M 376.00% | 32.776M 102.52% | 117.55M 258.65% | 234.91M 99.84% | 357.92M 52.36% | |
| EBITDA YoY % growth | -211.14M -68.91% | -294.63M -39.54% | -172.229M 41.54% | -191.921M -11.43% | -208.509M -8.64% | -227.243M -8.98% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -216.99M -69.40% | -308.39M -42.12% | -190.511M 38.22% | -206.897M -8.60% | -232.474M -12.36% | -236.279M -1.64% | -265.726M -12.46% | -264.191M 0.58% | -182.834M 30.79% | -85.662M 53.15% | 59.67M 169.66% | |
| Operating Margin | -388.52% | -320.24% | -299.86% | -1,512.74% | -5,784.37% | -6,949.37% | -1,641.91% | -806.05% | -155.54% | -36.47% | 16.67% | |
| EPS YoY % growth | -2.23 -7.21% | -2.91 -30.49% | -1.64 43.64% | -1.72 -4.98% | -1.73 -0.65% | -1.46 15.79% | -0.96 34.30% | -0.82 14.89% | -0.47 42.50% | -0.18 60.87% | 0.21 216.67% |
All data in USD
| Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.45 -1.09% | -0.46 2.34% | -0.45 -36.75% | -0.46 -15.37% | -0.47 -2.83% |
| Revenue Q2Q % growth | 1.491M -11.04% | 1.271M -33.97% | 1.271M -81.23% | 1.271M -58.65% | 1.453M -2.55% |
| EBITDA Q2Q % growth | -57.16M -91.86% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -55.513M -15.47% | -56.993M -11.60% | -59.136M -31.17% | -61.78M -17.95% | -63.223M -13.89% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | -0.40 13.04% | -0.44 | 0.04 | 9.28% |
| Q2 2024 Q2Q % growth | -0.33 38.89% | -0.48 | 0.15 | 31.92% |
| Q1 2024 Q2Q % growth | -0.47 -147.37% | -0.50 | 0.03 | 5.72% |
| Q4 2023 Q2Q % growth | -0.45 22.41% | -0.53 | 0.08 | 15.58% |
| Q3 2023 Q2Q % growth | -0.46 46.51% | -0.58 | 0.12 | 20.87% |
| Q2 2023 Q2Q % growth | -0.54 31.65% | -0.60 | 0.06 | 10.01% |
| Q1 2023 Q2Q % growth | -0.19 72.06% | -0.64 | 0.45 | 70.10% |
| Q4 2022 Q2Q % growth | -0.58 19.44% | -0.88 | 0.30 | 33.99% |
| Q3 2022 Q2Q % growth | -0.86 -91.11% | -0.91 | 0.05 | 5.60% |
| Q2 2022 Q2Q % growth | -0.79 -36.21% | -0.84 | 0.05 | 6.26% |
| Q1 2022 Q2Q % growth | -0.68 -41.67% | -0.78 | 0.10 | 12.89% |
| Q4 2021 Q2Q % growth | -0.72 -18.03% | -0.68 | -0.04 | -5.88% |
| Q3 2021 Q2Q % growth | -0.45 33.82% | -0.59 | 0.14 | 24.12% |
| Q2 2021 Q2Q % growth | -0.58 -65.71% | -0.54 | -0.04 | -7.83% |
| Q1 2021 Q2Q % growth | -0.48 -9.09% | -0.44 | -0.04 | -8.70% |
| Q4 2020 Q2Q % growth | -0.61 -64.86% | -0.40 | -0.21 | -52.15% |
| Q3 2020 Q2Q % growth | -0.68 -70.00% | -0.37 | -0.31 | -83.79% |
| Q2 2020 Q2Q % growth | -0.35 2.78% | -0.28 | -0.07 | -27.09% |
| Q1 2020 Q2Q % growth | -0.44 -46.67% | -0.40 | -0.04 | -10.86% |
| Q4 2019 Q2Q % growth | -0.37 -48.00% | -0.39 | 0.02 | 5.96% |
| Q3 2019 Q2Q % growth | -0.40 -29.03% | -0.38 | -0.02 | -4.08% |
| Q2 2019 Q2Q % growth | -0.36 2.70% | -0.33 | -0.03 | -7.82% |
| Q1 2019 Q2Q % growth | -0.30 -11.11% | -0.24 | -0.06 | -22.99% |
| Q4 2018 Q2Q % growth | -0.25 | -0.24 | -0.01 | -3.42% |
| Q3 2018 Q2Q % growth | -0.31 | -0.26 | -0.05 | -21.22% |
| Q2 2018 Q2Q % growth | -0.37 | -0.33 | -0.04 | -12.70% |
| Q1 2018 Q2Q % growth | -0.27 | -0.23 | -0.04 | -18.53% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | 3.074M 58.13% | 1.352M | 1.722M | 127.37% |
| Q2 2024 Q2Q % growth | 6.772M 625.83% | 1.437M | 5.335M | 371.26% |
| Q1 2024 Q2Q % growth | 1.925M -96.74% | 1.137M | 788K | 69.31% |
| Q4 2023 Q2Q % growth | 1.676M -96.22% | 1.626M | 50K | 3.08% |
| Q3 2023 Q2Q % growth | 1.944M -87.02% | 912.329K | 1.032M | 113.08% |
| Q2 2023 Q2Q % growth | 933K -94.97% | 5.639M | -4.706M | -83.45% |
| Q1 2023 Q2Q % growth | 58.98M 220.37% | 36.213M | 22.767M | 62.87% |
| Q4 2022 Q2Q % growth | 44.36M 159.87% | 17.058M | 27.302M | 160.05% |
| Q3 2022 Q2Q % growth | 14.98M 5.27% | 15.939M | -959K | -6.02% |
| Q2 2022 Q2Q % growth | 18.55M 38.33% | 13.14M | 5.41M | 41.17% |
| Q1 2022 Q2Q % growth | 18.41M 65.26% | 9.585M | 8.825M | 92.07% |
| Q4 2021 Q2Q % growth | 17.07M 7.36% | 10.945M | 6.125M | 55.96% |
| Q3 2021 Q2Q % growth | 14.23M 88.23% | 8.047M | 6.183M | 76.84% |
| Q2 2021 Q2Q % growth | 13.41M 145.16% | 6.433M | 6.977M | 108.46% |
| Q1 2021 Q2Q % growth | 11.14M 342.06% | 6.02M | 5.12M | 85.05% |
| Q4 2020 Q2Q % growth | 15.9M 467.86% | 4.973M | 10.927M | 219.73% |
| Q3 2020 Q2Q % growth | 7.56M 211.11% | 7.111M | 449K | 6.31% |
| Q2 2020 Q2Q % growth | 5.47M 93.97% | 13.495M | -8.025M | -59.47% |
| Q1 2020 Q2Q % growth | 2.52M -4.18% | 1.826M | 694K | 38.01% |
| Q4 2019 Q2Q % growth | 2.8M 68.67% | 1.832M | 968K | 52.84% |
| Q3 2019 Q2Q % growth | 2.43M 135.92% | 1.829M | 601K | 32.86% |
| Q2 2019 Q2Q % growth | 2.82M 173.79% | 1.187M | 1.633M | 137.57% |
| Q1 2019 Q2Q % growth | 2.63M 155.34% | 2.423M | 207K | 8.54% |
| Q4 2018 Q2Q % growth | 1.66M | 2.944M | -1.284M | -43.61% |
| Q3 2018 Q2Q % growth | 1.03M | 2.926M | -1.896M | -64.80% |
| Q2 2018 Q2Q % growth | 1.03M | 1.204M | -174K | -14.45% |
| Q1 2018 Q2Q % growth | 1.03M | 1.714M | -684K | -39.91% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | 9.47% | 0.27% | 0.27% |
| Revenue | 0% | 43.92% | 18.86% | 18.86% |